TAS-120 (futibatinib) is an orally available, irreversible FGFR1-4 inhibitor with a unique binding mode, targeting a unique cysteine in the P-loop of the FGFRs, rather than the Cys in the hinge region of FGFR4 as for roblitinib (above) or BLU9931 and fisogatinib. It is currently the most advanced irreversible FGFR inhibitor in clinical [...]
< 1 minute read
Sep. 18, 2021
Futibatinib: An Oral Irreversible FGFR1-4 Inhibitor
TAS-120 (futibatinib)
oral irreversible FGFR1-4 inhibitor in Ph. I-III trials for FGFR+ advanced tumors from structure-based design Cancer Res., Sep. 24, 2020 Taiho Pharmaceutical, Tokyo, JP
Loading...
